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Skeletal muscle atrophy induced by denervation and metabolic dis-
eases has been associated with increased ubiquitin ligase expression.
In the present study, we evaluate the influence of androgens on muscle
ubiquitin ligases atrogin-1/MAFbx/FBXO32 and Murf-1/Trim63 ex-
pression and its correlation with maintenance of muscle mass by using
the testosterone-dependent fast-twitch levator ani muscle (LA) from
normal or castrated adult male Wistar rats. Gene expression was
determined by qRT-PCR and/or immunoblotting. Castration induced
progressive loss of LA mass (30% of control, 90 days) and an
exponential decrease of LA cytoplasm-to-nucleus ratio (nuclear do-
main; 22% of control after 60 days). Testosterone deprivation induced
a 31-fold increase in LA atrogin-1 mRNA and an 18-fold increase in
Murf-1 mRNA detected after 2 and 7 days of castration, respectively.
Acute (24 h) testosterone administration fully repressed atrogin-1 and
Murf-1 mRNA expression to control levels. Atrogin-1 protein was
also increased by castration up to 170% after 30 days. Testosterone
administration for 7 days restored atrogin-1 protein to control levels.
In addition to the well known stimulus of protein synthesis, our results
show that testosterone maintains muscle mass by repressing ubiquitin
ligases, indicating that inhibition of ubiquitin-proteasome catabolic
system is critical for trophic action of androgens in skeletal muscle.
Besides, since neither castration nor androgen treatment had any
effect on weight or ubiquitin ligases mRNA levels of extensor digi-
torum longus muscle, a fast-twitch muscle with low androgen sensi-
tivity, our study shows that perineal muscle LA is a suitable in vivo
model to evaluate regulation of muscle proteolysis, closely resembling
human muscle responsiveness to androgens.
muscle atrophy; proteasome; androgen; nuclear domains; levator ani
muscle
SKELETAL MUSCLE FIBERS ARE highly adaptable to changes in
neuromuscular transmission, atrophying in response to either
disuse or denervation (27, 52) and hypertrophying after elec-
tromechanical stimulation through exercise (42, 52). Several
endocrine factors also regulate muscle trophic status; particu-
larly, androgenic hormones have a well established anabolic
action (8). Low testosterone levels have been associated to
decreased human muscle mass (3, 20, 43, 58), whereas testos-
terone administration has been used to improve general muscle
function in elderly men (17). These results show that general
human musculature clearly responds to androgen deprivation
or administration. In fact, anabolic androgens increase muscle
mass and strength in several atrophic states, such as cachexia in
cancer, AIDS, and burn patients (25, 29, 33). Treatment with
nutritional supplementation alone is ineffective, since proteol-
ysis must be inhibited for substantial mass recovery (36).
There are several proposed mechanisms for the primarily
anabolic actions of androgens (33). Classically, androgens
exert their effects by increasing general muscle protein synthe-
sis directly (13, 21, 34) or though increased activation (32) and
proliferation (53) of myogenic satellite cells (64), progenitor cells
that express high levels of androgen receptors (AR) (54).
Still, there is a lack of effective models to evaluate testos-
terone action in vivo, because at adulthood rodent skeletal
muscles in general display a very modest or undetectable
response to sex hormones (1, 2, 12, 14, 22, 23, 37). This low
sensitivity to androgens clearly contrasts with the marked
responses of the sexually dimorphic perineal muscles of rat,
bulbocavernosus (BC), and levator ani (LA) muscles, which
play an important role in copulation. Castration induces atro-
phy of these muscles (55, 62), with a significant reduction of
synaptic proteins (9, 22, 24). In fact, hypertrophic action in the
LA is a good predictor of effective anabolic androgens (30,
33). Also, although 50% of human myonuclei are AR (54),
only 7% of myonuclei express AR in the extensor digitorum
longus (EDL) of the rat (46). Therefore, it is to be expected that
LA, with 74% AR myonuclei (46), mimic more closely
human muscles than the general nonresponsive musculature of
the rat.
Interestingly, LA has been recently used to evaluate the
action of androgens over protein synthesis signaling (63),
satellite cell function (47), and synaptic adaptation (49), but not
androgenic regulation of proteolysis. Proteolytic activity is a
hallmark in several models of skeletal muscle atrophy, and the
ubiquitin-proteasome system (UPS) is responsible for up to
80–90% of cellular protein degradation (36). Several ubiquitin
ligases catalyze the transfer of ubiquitin from a carrier protein
to UPS substrates, thereby targeting these proteins for degra-
dation by the 26S proteasome with a chain of ubiquitin mole-
cules (36). Regulation of muscle proteolysis involves ubiquitin
ligases, such as atrogin-1/MAFbx/FBXO32 (26) and Murf-1/
Trim63 (10), specifically upregulated in muscle atrophy. Also,
overexpression of atrogin-1 leads to atrophy of cultured myo-
tubes, whereas atrogin-1 or Murf-1 knockout animals are
resistant to muscle atrophy (10).
Elucidation of components involved in repression of cata-
bolic signaling might lead to a better understanding of the
trophic action of androgens in skeletal muscle and the delete-
rious muscle wasting effects of aging and hypogonadism.
Therefore, a thorough knowledge of signaling in a model of
skeletal muscle atrophy specifically caused by androgen depri-
Address for reprint requests and other correspondence: R. O. Godinho, Dept.
of Pharmacology, Universidade Federal de São Paulo, Rua Três de Maio, 100,
3rd floor, São Paulo, SP, Brazil 04044-020 (e-mail: godinho@unifesp.br).
J Appl Physiol 108: 266–273, 2010.
First published November 19, 2009; doi:10.1152/japplphysiol.00490.2009.
8750-7587/10 $8.00 Copyright © 2010 the American Physiological Society http://www.jap.org266
vation seems justified. Because rat LA displays rapid and
progressive responses to androgens, the goal of this study was
to determine the in vivo effect of androgen on UPS, analyzing
the possible change of skeletal muscle ubiquitin ligases atro-
gin-1, and Murf-1 expression induced by hormone deprivation
and/or administration.
MATERIAL AND METHODS
Animals and treatments. Adult male Wistar rats from the institu-
tional animal care facility were maintained on a 12:12-h light-dark
cycle, with standard chow and water ad libitum. Rats were randomly
assigned to control (N) or castrated groups for 2 (C2), 3 (C3), 6 (C6),
7 (C7), 15 (C15), 30 (C30), 60 (C60), or 90 (C90) days. As illustrated
in Fig. 1, experimental groups treated with testosterone propionate
(TP; 4 mg/kg sc; Sigma Aldrich, St. Louis, MO) consisted of
C15TP7 (rats castrated 15 days before and treated for 7 days with
TP at days 8, 11, and 14), C7TP5 (rats castrated 7 days before and
treated for 5 days with TP at days 2, 4, and 6), C7TP1 (rats castrated
7 days before and then treated with a single dose of TP on day 6), and
C3TP1 (rats castrated 3 days before and then treated with a single
dose on day 2).
Castration reduces plasma testosterone by 82% after 1 day and
further to constant, nondetectable levels (0.04 ng/ml) after 5 days
(44). Therefore, testosterone t1/2 was at most 8 h, and all castrated
groups were intensely androgen deprived. Testosterone propionate
administrations were modified from Maróstica et al. (41) to achieve
plasma testosterone concentrations similar or just slightly higher than
those of control animals. Testosterone propionate is a more lipophilic
testosterone ester that is slowly absorbed after injection in oil vehicles.
Peak plasma concentration occurs after 24 h, and half-life is also 24
h; therefore, a thrice-weekly scheme of testosterone propionate ad-
ministration was chosen for reduced animal manipulation stress (18).
Castration was performed as previously described (22) under 75
mg/kg ketamine and 12 mg/kg xylazine anesthesia. All animals were
killed by decapitation at 120 days of age (C2–30), 150 days (C60), or
180 days (C90), and seminal glands (SG), LA, and extensor digitorum
longus (EDL) muscles were dissected, weighted, and processed as
described below. Preliminary experiments with tissues from sham-
operated rats or animals injected with vehicle were also tested. Since
no significant change was observed when these two experimental
groups were compared with intact rats, all subsequent experiments
were performed with tissues from intact, age-matched rats as controls.
In another set of experiments, adult male Swiss mice, obtained and
maintained as described for rats, were randomly assigned to control
(N); castrated 3 days (C3), or castrated 3 days before and then treated
with a single dose of 4 mg/kg TP sc on day 2 (C3TP1). All
experimental procedures were approved by the institutional ethics
committee (protocol no. 1604/2007).
Quantitative analysis of nuclear domains. Skeletal muscles were
fixed overnight with 4% formaldehyde at 4°C, washed with PBS, pH
7.4, perfused, and then incubated for 1 h with a 5 g/ml Hoechst dye
33258 (Invitrogen, Carlsbad, CA) solution on DMEM containing 10%
horse serum for nuclear staining (19). Then muscles were washed with
DMEM and PBS, pH 7.4, and dissected under a stereoscope by
separation of progressively thinner bundles of fibers.
Images of stained myofibers were acquired on a confocal micro-
scope (LSM 510 META, Carl Zeiss Optical, Chester, VA), equipped
with a multiphoton laser (Coherent, Santa Clara, CA), with excitation
at 360 nm and emission at 460 nm, a 40 objective (oil immersion,
NA 1.3; Carl Zeiss Optical, Chester, VA), and a CDC camera
(AxioCam, Carl Zeiss Optical). Images were obtained as z-series of
1-m sections and digitalized for tridimensional reconstruction of
myofibers.
Myofiber volumes were approximated as cylindric and calcu-
lated as:
Volume (Diameter
2
)2 Length
Confocal images were processed with Zeiss LSM Image Browser
4.2.0.121 (http://www.zeiss.com/micro) and measured with ImageJ
1.32 (http://rsb.info.nih.gov/ij).
RNA isolation and quantitative RT-PCR. RNA was isolated using
TRIzol (Invitrogen, Carlsbad, CA) from individual skeletal muscles.
Reverse transcription into cDNA was performed using 1 g of total
cellular RNA, 20 pmol oligo(dT) primer (Invitrogen) and Advantage
ImProm-II reverse transcriptase (Promega, Madison, WI). Real-time
PCR was carried out on an ABI7000 sequence detection system (Applied
Biosystems, Foster City, CA), using SuperScript III Platinum SYBR
Green One-Step qRT-PCR Kit with ROX (Invitrogen), and primers rat
atrogin-1 (NM_133521) forward 5=-TGAAGACCGGCTACTGTGGAA-
GAGAC-3= and reverse 5=- TTGGGGTGAAAGTGAGACGGAGCAG-3= (am-
plimer size, 486 bp), rat Murf-1 (AY059627.1) forward 5=-TCGACATC-
TACAAGCAGGAA-3= and reverse 5=-CTGTCCTTGGAAGATGC-
TTT-3= (amplimer size, 194 bp), rat cyclophilin B (NM_022536) forward
5=-AGACGAACCTGTAGGACGAG-3= and reverse 5=-AGATGCTCT-
TTCCTCCTGTG-3= (amplimer size, 197 bp), mouse atrogin-1
(NM_026346) forward 5=-GCAGAGAGTCGGCAAGTC-3= and reverse 5=-
CAGGTCGGTGATCGTGAG-3= (amplimer size, 142 bp), mouse MuRF-1
(NM_001039048.2) forward 5=-TGTGCAAGGAACACGAAG-3= and re-
verse 5=-TGAGAGATGATCGTCTGC-3= (amplimer size, 208 bp), and
mouse cyclophilin B (NM_011149.2) forward 5=-AAGGACTTCAT-
GATCCAGGG-3= and reverse 5=-TGACATCCTTCAGTGGCTTG-3= (am-
plimer size, 301 bp). Primers were previously tested in conventional
reverse transcription PCR, where a single band of the expected amplimer
size was obtained. Relative quantitation of mRNA levels was plotted as
fold increase compared with noncastrated control group values. Ciclo-
phylin B (CB) was used for normalization (4). Ct values were averaged,
and Ct values (target gene Ct minus CB Ct) were calculated for each
group. Ct values (Ct from sample group minus Ct from control
group) were calculated, and mRNA amplification was determined as
2Ct (39).
Fig. 1. Experimental treatments with testosterone propionate (TP). Group
C15TP7 was castrated for 15 days and treated with three doses of 4 mg/kg
TP sc from day 8 to day 15 of castration; group C7TP5 was castrated for 7
days and treated with three doses of 4 mg/kg TP sc from day 3 to day 7 of
castration; group C7TP1 was castrated for 7 days and then treated with a
single dose of 4 mg/kg TP sc on the last day of castration; group C3TP1 was
castrated for 3 days and then treated with a single dose of 4 mg/kg TP sc on
the last day of castration. Lines between filled circles show castration periods;
gray rectangles show duration of treatments with TP; each arrow marks a 4
mg/kg TP sc administration.
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Immunoblotting. Samples (40 g) of skeletal muscle protein were
dissolved in 0.05 M Tris · HCl, pH 7.4 with 0.5 mol/l NaCl and 0.1%
Tween-20 (TBS-T) and loaded onto a 10% polyacrylamide gel with
SDS. After electrophoresis, proteins were transferred (TransBlot Semi
Dryer, Bio-Rad, Hercules, CA) to a nitrocellulose membrane (Trans-
blot 0.45 M, Bio-Rad) at 10 mA/20 min, with 39 mM glycine, 48
mM Tris, 10% SDS on water/methanol 1:5 (vol/vol). Membranes
were stained with Ponceau Red, blocked with 10% nonfat milk on
TBS-T for 1 h and incubated with rabbit anti-rat atrogin-1 primary
IgG (a gift from Dr. Stewart H. Lecker, Renal Unit, Beth Israel
Deaconess Medical Center, Boston, MA) (5) on blocking buffer for 2
h at room temperature. Secondary peroxidase-conjugated goat anti-
rabbit IgG antibodies (a gift from Dr. Eduardo B. Oliveira, FMRP-
USP, Ribeirão Pret, Brazil), diluted 1:10,000 on blocking buffer, were
applied to previously washed membranes for 2 h at room temperature.
Development was performed by the enhanced chemiluminescence
method with luminol (Santa Cruz Biotechnology, Santa Cruz, CA).
Atrogin-1 pixel density levels were evaluated with NIH ImageJ 1.32
software, normalized to Ponceau Red density, and expressed as
percentage of control values.
Statistical analysis. Results were expressed as means  SE, except
where specified. For determination of statistical differences between
averages, one-way ANOVA followed by Dunnett’s post hoc test was
used. All analyses were performed using GraphPad Prism for Win-
dows 5.01. Statistical significance level was fixed at 5% (P  0.05).
RESULTS
Androgenic regulation of levator ani muscle mass and
morphology. Neither castration for 2–90 days nor androgen
treatment for 1, 5, or 7 days significantly changed the body
weight of control adult male rats (4-mo-old N 	 327.2  14.5
g; 5-mo-old N 	 360.0  7.2 g; 6-mo-old N 	 399.3  24.7
g). However, androgenic deprivation was successfully induced
by castration, as shown by progressive atrophy of the seminal
gland, an androgen-dependent organ of the male reproductive
tract that reached 20% of control weight (N 	 210.5  11.2
mg; Fig. 2A) 30 days after castration.
Comparatively, castration induced a progressive atrophy of
the androgen-sensitive LA muscle, which reached 30% of
control weight (N 	 164.3  6.3 mg; Fig. 2A) after 90 days.
Androgen administration for 1 or 5 days did not significantly
increase LA muscle weight compared with values from non-
treated animals subjected to the same castration periods (C3 	
149.8  0.9 mg; C7 	 124.9  6.6 mg, respectively). How-
ever, when rats castrated for 15 days were treated with testos-
terone propionate from days 8 to 15 (C15TP7), LA atrophy
was attenuated by 46% compared with nontreated castrated rats
(C15 	 77.7 mg  2.3 mg; Fig. 2B). This androgen treatment
also completely reversed SG atrophy induced by castration
after 15 days (C15 	 109.4  3.7 mg).
It is well known that atrophy of the androgen-deprived LA
muscle occurs with no loss of skeletal muscle fibers (56, 60),
whereas androgen treatment increases LA myofiber diameter
(31). To follow the progressive adaptation of the atrophic fiber,
we evaluated the effect of androgen deprivation on muscle
fiber morphology of the LA muscle. We found an exponential
decrease on myofiber diameter after castration, up to 39% of
control values (N 	 35.3  0.4 m; Fig. 3) after 60 days.
Castration had no effect on EDL myofiber diameter compared
with control (N 	 36.7  0.7 m; Fig. 3).
Although androgen deprivation increased the number of
apoptotic nuclei (Fig. 4B), which may lead to loss of some
myonuclei, it was not sufficient to maintain a constant myo-
nuclear domain. In fact, cytoplasm-to-nucleus ratio decreased
progressively and in parallel with LA myofiber diameter (Figs.
3 and 4A), reaching 22% of control value 60 days after
castration (Fig. 4C).
Effects of androgen deprivation and replacement on ubiq-
uitin ligase expression. To investigate the molecular basis of
LA atrophy, we analyzed the expression of atrogin-1, an F-box
ubiquitin-ligase member whose expression is increased several-
fold in a variety of muscle wasting conditions (26, 50) and
Murf-1, a RING finger ubiquitin ligase also upregulated during
muscle atrophy (10, 50). Atrogin-1 mRNA expression peaked
at a 31-fold increase after just 2 days of hormonal deprivation,
returning to control levels after 30 days (Fig. 5A). Interestingly,
even though androgen treatment for 24 h was too short to affect
LA weight, it completely abolished the 20-fold increase of
atrogin-1 mRNA induced 3 days after castration (C3TP1;
Fig. 5B). Longer treatments with testosterone propionate
(C15PT7), which inhibit the progression of LA atrophy (Fig.
2B), also recovered atrogin-1 mRNA level to control values
(data not shown). These results show that LA atrophy induced
Fig. 2. Castration successfully induces atrophy of the androgen-sensitive
seminal gland (SG) and levator ani muscle (LA) but does not change extensor
digitorum longus (EDL) muscle weight. A: adult male rats were castrated for
0, 2, 3, 7, 15, 30, 60, and 90 days, and decreased SG weight was used as a
control of successful castration. C60 and C90 values were normalized to
age-matched controls (5-mo-old and 6-mo-old, respectively). B: although
castration (C) significantly reduces LA wet weight, when rats were castrated
for 15 days and treated with testosterone propionate (3 doses of 4 mg/kg sc)
from day 8 to day 15 of castration (C15TP7), LA muscle atrophy was
significantly attenuated. Each point represents mean  SE of 3–4 individuals.
*Significantly different from controls (0; P  0.05). **Significantly different
from castrated (C15; P  0.05).
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by castration is preceded by increased atrogin-1 mRNA ex-
pression. Conversely, androgen administration promptly re-
versed the effect of castration on atrogin-1 mRNA expression,
which might explain effective prevention of LA atrophy later.
Ultrashort treatment (6 h) with androgen, however, was not
enough to significantly reduce atrogin-1 mRNA expression
(data not shown).
Neither castration nor androgen treatment had any effect on
EDL weight (N 	 186.9  16.2 mg; Fig. 2A) or atrogin-1
mRNA levels (Fig. 5E) compared with controls. Interestingly,
atrogin-1 mRNA relative expression in control EDL muscle
was 28-fold higher than the expression observed in LA muscle,
and castration increased LA atrogin-1 transcript, abolishing the
differences between both muscles.
Taking into account that biological impact of changes in
atrogin-1 transcript levels depends on whether they are fol-
lowed by changes in the encoded proteins, atrogin-1 protein
expression was evaluated through an immunoblotting assay.
Castration induced a progressive increase in LA atrogin-1
protein content up to 2.7-fold at 30 days (Fig. 6). When rats
were castrated for 15 days and treated with testosterone pro-
pionate from days 8 to 15 (C15TP7), atrogin-1 protein
expression returned to control levels (Fig. 6). As observed in
transcript analysis, castration had no effect on EDL atrogin-1
protein, which was higher in EDL than in LA.
In LA, testosterone appears to have broad control over
muscle ubiquitin proteasome system and also modulates
Murf-1 mRNA expression. After castration, there was an
18-fold increase in LA Murf-1 mRNA, which was maximal
after 7 days and quickly returned to control levels after 15 days
(Fig. 5C). Androgen treatment for 24 h also abolished the
increment of Murf-1 mRNA induced after 7 days of castration
(Fig. 5D). Neither castration nor androgen treatment had any
effect on EDL Murf-1 mRNA levels compared with controls
(Fig. 5E). In parallel to atrogin-1 mRNA results, Murf-1
mRNA is five times more abundant in control EDL than in LA.
As seen with atrogin-1, castration increased LA Murf-1 tran-
script and inverted the pattern between muscles.
We also compared the effects of testosterone on atrogin-1
and Murf-1 mRNA from rat LA with those on mouse LA/BC
transcripts. We found that 3 days after castration atrogin-1 and
Murf-1 mRNA levels increased by five- and threefold, respec-
tively (Fig. 7). When mice were castrated for 3 days and then
treated with testosterone propionate through the last day, atro-
gin-1 and Murf-1 mRNA levels were similar to control (Fig. 7).
Fig. 3. Castration decreases myofiber diameter of the male rat LA. Adult male
rats were castrated for 0, 7, 15, 30, 60, and 90 days, and myofiber diameter was
determined on isolated myofibers from both muscles. LA myofiber diameter
decreased exponentially with castration. There were no changes on EDL in all
castration periods considered. Each point represents mean  SE of random
myofibers (11–53) from 3–4 individuals. Symbols are larger than SE. *Sig-
nificantly different from controls (0; P  0.05).
Fig. 4. Castration leads to decreased myofiber diameter and nuclear domains in
the LA. A: castration for 7 (C7) or 60 days (C60) significantly reduced LA
myofiber diameter, volume, and cytoplasm-to-nucleus ratio compared with
fibers from control rats (N). Z-axis projections were obtained through confocal
microscopy of Hoechst 33258-stained isolated myofibers and superposed on
differential interference contrast images (representative images). B: fluores-
cence images of Hoechst 33258-stained cryosections showed a representative
fragmented myonuclei (arrowhead) in a LA myofiber after castration for 2 days
(C2). No fragmentation was seen in control muscles (N). C: cytoplasm-to-
nucleus ratio results (nuclear domain) of myofibers from 3 individuals were
quantitated. Each point represents mean  SE of random myofibers (14–29)
from 3 individuals. Some symbols are larger than SE. *Significantly different
from controls (0; P  0.05).
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DISCUSSION
In the present study, we used the LA muscle of the adult
male rat as a particularly sensitive model to study the effects of
androgen on skeletal muscle mass and muscle ubiquitin ligases
atrogin-1 and Murf-1 expression. Here, muscle atrophy was
induced specifically by removal of the androgen, without
invasive neuromuscular lesion, as in denervation, or systemic
metabolic disturbance caused by cachexia or fasting.
LA atrophy induced by hormonal withdrawal was paralleled
by a progressive decrease in nuclear domains due to myofiber
volume reduction (Fig. 3), indicating that apoptotic loss of
myonuclei is not widespread enough to maintain cytoplasm-
to-nucleus ratio in the atrophied fiber. These data are in
agreement with those of Nnodim (48), who showed a de-
creased distance between myofiber nuclei 8 wk after castration.
Trophic effects of androgens on skeletal muscle involves
multiple mechanisms including increment of protein synthesis
(34), recruitment of myogenic satellite cells (32), and/or re-
pression of catabolic pathways and factors, such as myostatin
(45) and glucocorticoid receptor signaling (65, 67). Here, our
results give new insight to this field, showing that androgens
act in vivo to quickly and largely repress expression of atro-
gin-1 and Murf-1, which affect UPS activity, a system respon-
sible for most proteolysis in the cell (36). Our results showed
that androgen withdrawal induces a 31-fold increase in atro-
gin-1 and 18-fold increase in Murf-1 mRNA content (Fig. 5).
These effects were larger than those observed in other models
of severe skeletal muscle atrophy induced by cachexia or
fasting (26), while similar to those seen in surgically dener-
vated muscles (50).
There are some candidate pathways for androgenic regula-
tion of atrogin-1 and Murf-1 expression. For instance, atro-
gin-1 regulation is known to involve FOXO3a, a member of
the forkhead box (FOXO) transcription factor family. FOXO3a
is inactivated through phosphorylation by several kinases (51),
such as the phosphatidylinositol-3 kinase (PI3K)/Akt pathway
Fig. 5. Androgen inhibits ubiquitin ligase mRNA
expression in the LA of male rats. A: adult male
rats were castrated for 0, 2, 3, 7, 15, or 30 days;
atrogin-1 mRNA expression increased after only 2
days of castration and returned to control levels
after 30 days. B: when rats were castrated for 3
days and then treated with a single dose of 4 mg/kg
TP sc on the last day (C3TP1), atrogin-1 mRNA
returned to control levels (N), whereas nontreated
rats castrated for 3 days (C3) showed a 20-fold
increase in atrogin-1 mRNA; castration for 7 days
and then treatment with three doses of 4 mg/kg TP
from day 3 to day 7 (C7TP5) also reduced
atrogin mRNA compared with nontreated rats cas-
trated for 7 days (C7). C: Murf-1 mRNA expres-
sion also increased after 7 days of castration and
returned to control levels after 15 days. D: when
rats were castrated for 7 days and then treated with
a single dose of 4 mg/kg TP sc on the last day
(C7TP1), Murf-1 mRNA returned to N, whereas
nontreated rats castrated for 7 days (C7) showed an
18-fold increase in Murf-1 mRNA. E: castration
had no effect on EDL atrogin-1 or Murf-1 mRNA.
Both transcript levels were higher in EDL than in
LA from control rats. Each point or bar represents
the mean SE of 3–6 individuals, normalized to
expression of each gene in control rat LA (0).
Standard errors were calculated as 2SE of Ct values.
*Significantly different from controls (P  0.05).
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recruited by insulin-like growth factor 1 (IGF-1). Akt phos-
phorylates FOXO3a, blocking its nuclear translocation and
thus decreasing atrogin-1 expression and protein degradation.
Interestingly, androgen deprivation reduces LA IGF-1 content,
whereas dihydrotestosterone treatment increases its amount
(63), suggesting that androgens might act indirectly through
the trophic IGF-1 pathway. Anabolic androgens might repress
atrogin-1 expression through other mechanisms, since Zhao
et al. (66) did not see changes in phosphorylated FOXO3a after
treatment of AR-transfected C2C12 cells with testosterone.
Since disruption of the AR DNA binding domain does not
block androgen-mediated atrogin-1 promoter repression, the
authors suggest an indirect inhibition mediated by Oct-1 (66).
In vivo atrogin-1 expression may also be affected by localized
changes in phosphorylated FOXO or even other pathways,
such as an indirect inhibition of atrogin-1 promoter mediated
by Oct-1 (66), p38 mitogen-activated protein kinase (p38
MAPK) (38), or NF-
B, whose activity is also implicated in
skeletal muscle atrophy (36). These signaling pathways are still
under investigation in our laboratory.
As for Murf-1, our study is the first to demonstrate upregu-
lation of its mRNA after androgen deprivation in vivo. The
mechanisms involved are unknown, but Murf-1 promoter has a
highly conserved glucocorticoid response element (61) that
could potentially mediate direct inhibitory AR binding (16).
Another recent report demonstrated the relevance of extracel-
lular signal-regulated kinases (ERK) as yet another androgen-
sensitive pathway that might regulate either Murf-1 or atro-
gin-1 expression (52a).
The possible regulation of ubiquitin ligases by androgenic
hormones was recently questioned by MacLean et al. (40), who
did not detect increased expression of atrophy-related ligase
genes at gastrocnemius muscle of AR knockout mice. In fact,
the low responsiveness of mouse muscle to androgenic action
is consistent with the inability of castration to increase atro-
gin-1 and Murf-1 mRNA at EDL of adult rat. The levels of
atrogin-1 and Murf-1 in EDL, even in control adult male rats
with normal serum testosterone, were high (Figs. 5E and 6),
indicating that physiological levels of androgens are not
enough to repress ubiquitin ligases in EDL, probably due to
low AR expression (2, 35). Therefore, our results strongly
support the idea of a normal pattern of low sensitivity of
general rodent musculature to androgen, whereas adult rat LA
provides a model in which androgen-mediated signaling is
amplified.
Since expression of ubiquitin ligases is higher in EDL, it is
likely that its protein turnover is faster than that of LA. A
corroborating example is acetylcholinesterase (AChE), whose
activity is higher in LA than in EDL, whereas castration
reduces total LA AChE activity to EDL levels (22). AChE is
intensely degraded by endoplasmic reticulum-associated UPS
(7), and testosterone could repress this degradation and in-
crease AChE content in LA through reduced ubiquitin ligase
expression.
Conversely, Beehler et al. (6) proposed that previously
described apoptotic phenomena (11) thoroughly explain mus-
Fig. 6. Castration induces a linear increase of atrogin-1 protein in the rat LA.
A: castration for 15 days and treatment with testosterone propionate (3 doses
of 4 mg/kg sc) from day 8 to day 15 of castration (C15TP7) significantly
reduced atrogin-1 protein expression to control levels (0). B: adult male rats
were castrated for 0 to 30 days, and protein samples from LA and EDL were
used for immunoblotting analysis with anti-atrogin-1 antibody. C: expression
was determined relative to Ponceau red staining through densitometric analy-
sis. Each bar represents mean  SD of 2–5 individuals.
Fig. 7. Androgen also inhibits ubiquitin ligase mRNA expression in the
androgen-dependent perineal muscles of male mice. Castration for 3 days (C3)
increased both atrogin-1 and Murf-1 mRNA expression compared with con-
trols (N). When mice were castrated for 3 days and then treated with a single
dose of 4 mg/kg TP sc on the last day (C3TP1), atrogin-1 and Murf-1 mRNA
returned to control levels. Perineal muscles levator ani and bulbocavernosus
were pooled from each individual. Each bar represents the mean  SE of 3
individuals, normalized to expression of each gene in control mice. Standard
errors were calculated as 2SE of Ct values.
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cle mass loss in the androgen-deprived LA instead of protea-
some activation, since treatment with proteasome inhibitor
bortezomibe (3 mg/kg) has no effect on atrophy induced by
10-day castration. However, as observed following denervation
(50), we showed here that LA atrogin-1 and Murf-1 mRNA
increased drastically and rapidly after castration (Fig. 5, A and
C), preceding any loss of muscle mass (Fig. 2A). Probably,
inefficiency of the bortezomibe treatment described by Beehler
et al. (6) only shows that UPS activation is still in its early
phases after 10 days of castration or that effective dose for
proteasome inhibition changes with the target and/or atrophy
model.
In this study, we also address whether mice ubiquitin ligases
are repressed by androgen. In fact, similar to rat LA, castration
increases atrogin-1 and Murf-1 mRNA, whereas androgen
treatment decreases it (Fig. 7). The detection of a conserved
response in mice gives new perspectives for further studies of
androgenic repression of ubiquitin ligases and proteolysis us-
ing knockout mice, including atrogin-1/ and Murf-1/
mice themselves (10).
Meanwhile, we have shown that testosterone quickly and
widely inhibits the expression of ubiquitin ligases atrogin-1
and Murf-1 in vivo, which may be critical for the anabolic
action of sex male hormones. Deprivation of androgens, espe-
cially in conditions such as aging and hypogonadism, is there-
fore likely to induce loss of muscle mass through degradation
of substrates of atrogin-1 and Murf-1, such as myogenic factor
MyoD (59) and contractile machinery proteins titin or troponin
I (15). Moreover, the high sensitivity to androgen makes the rat
perineal LA muscle an outstanding model to study muscle
atrophy instead of general rat musculature, which responds
much more poorly to androgens than human muscle. Identifi-
cation of androgenic regulation of ubiquitin ligases atrogin-1
and Murf-1 opens leeway to characterization of common
mechanisms involved in skeletal muscle atrophy and to ana-
bolic therapy targets with far fewer side effects than those
currently used in practice.
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